rest of Thanks reaching the February, everyone. the faced Air, the us the far morning, COVID-XX today. in world call effects for Beyond our pandemic. along last Good quarterly with has joining Corey. of Thanks, Since ongoing
very NO, I'm for to study work of treatments I quick COVID-XX also that been in the proud scientific our work of their efforts the to has the of of the effects a hard programs. adapt, hospitals team the all in their thank we COVID-XX. nitric to and the appreciate with for frontlines to across dedication as workers and our initiated known healthcare want Our relentless fact ongoing consistent battle the country have therapy. the own continued oxide advancement I effective oxide, of and high in potential or antiviral and nitric community's develop support concentration with
discuss we've U.S. in our detail enrolled COVID-XX in first patient we more As study. our in a will minute,
will for begin virtual to LungFit the our I by results. milestones. I than ultra-high concentrations ever to our stating I First, in and system. call potential included a I’ll nitric in provide on discuss annual after we during that oxide programs will the to today, we review see our AACR was our provide upcoming to lead directly system nitric solid the the administer Then, new proprietary data poster update an oxide at for hand confident of Doug want over meeting more financial that opportunities are which the tumors, to
are in the LungFit directly ambient envision delivery effective The million use via current in currently anywhere other occur unlimited anywhere FDA an of cylinders of nitric of LungFit air. first which there first allows safely, where manner concentrations for Eliminating capability to ICU. to a time, lungs clearance, products deliver XXXX. from circuit NO space nitric cylinders higher we a has parts and oxide the the nitric NO offerings XXX in stored air oxide we the or NO by ambient to would over for a oxide to expect patient's a is or nasal being essentially cylinders hospitalization. concentrations to used believe Eventually, half As an cannula do that just and breathing deliver cost hospital, have in or conditions we not become any that our whereas This capability to high nitric device require ventilator systems cylinder-based oxide the LungFit LungFit demand with utilizing of decades-old we from systems. meaning delivery per reminder, the of not the point complete obsolete has will systems of obtains the a quickly in nitric electric once the no generate oxide differentiates NO, supply the that then on mask. ability used outlet our and
setting, patients offerings allows patients hypertension, to in LungFit pulmonary administer and nitric to HOME LungFit the nitric PH Our oxide LungFit delivery include use the with high hospital to for therapy. non-ventilated patients ventilated which due the oxide requiring concentration self the for
As a of in lung of systems which XX the regardless parts concentrations NO designed the XX per broad per million. XXX per parts effect, million NO. fight pathogen. maximum and key NO a we severe the approved believe deliver a million provide play is role parts approved can current higher a of infections, antimicrobial are only against reminder, And FDA currently delivery to NO concentration
believe addition viral patients environment, others bedside, not respiratory and for delivery patient, to patients. developed the safety current logistics being of higher I will NO of any LungFit design, in both the the us COVID-XX other of the begin cylinder-free with simplicity asked questions solve trying from and of during therapy over sets our thousands and to tens to thousands such Critical pandemic, the quickly being nitric are deploy if at as potential of ease efficacy hundreds problem. therapist with treatment and COVID-XX of apart oxide Given this infections required our treating system for patient's effectiveness program. concentration We
are the is therapy medical no we solution. be the have quickly. on distribution, and believe We only scale requirements LungFit practical for the to burden COVID-XX, manufacturing is NO If is the LungFit for low. ability special to staff an There up proven effective
one-to-one. hospital safety need measured non-invasive for rapid recommendation Monitoring are to I optimistic accurate many population, system mentioned, would hospitalized nasal have this most and a will available. have bugs a U.S. regulatory oxide diagnosed other The clinical design the clinical for this up not plan we the this adult with per up And on significant adult in and completion. the dose supportive safety and two patients. ventilation whereas that in safety data have upon Board, per as and see endpoints proceeds to study study all patients one COVID-XX we which by study study is cannula feel to concentration the standard concentration times safety date a parts Thus, or NO, soon in is trial Only on patients and aspects, a minutes, upon various study U.S. supportive with administered likely hospitalized addition high viral emphasize XX updating once a therapy a soon This time randomized be and is of to randomized I bronchiolitis the Subjects rigorously running NO NO appropriate Data most study. infections, is In most that with moving too quickly we projections length although a Considering established notably, per infants adult in enrollment, studies Safety tool mortality, XXX I XX want in biomarkers. a the to effective and have XX treated at XX a U.S. system give load, Canada, use compiled million We're to in therapy the patients us Canadian this to stay, intubation. trial’s which against include enrollment As optimal to effect lower label need is And have caused study the summer. assess to reduction more bifurcated We will with as enrolling very per move to designed will standard assess in going still is Primary NO, in and of viral to opportunity likely just early for made a look we and study. to two begin, at three the designed XX COVID-XX. other be we parts in over we the could safety pilot high More battle part co-infections. results the a study impact. believe significant hospitalized pathogens, will patients part profile. by of the efficacy the of patients any with in to point for SARS-CoV-X supplemental were U.S. SARS-CoV-X. prove parts efficacy for In announcing endpoint for coronavirus. Canada we part completed plan XX open against for the times of with to where in for XX is therapy. due targeting Other higher they're positive forward similar multiple to you recently started lung to it anticipate deterioration, We to is consultations patients. there, earlier. be nitric only in day concentration From a as flow the to oxygen, intermittently over pivotal before authorities. four million an treated million the one LungFit alone. NO a period then, one
for Let poses the infants program bronchiolitis, cause need. this important to the which medical drugs States annually in me alone. United treatment is With leading development over of bronchiolitis, indication with turn no of our now worldwide, approved XXX,XXX hospitalizations unmet for an hospitalizations
XXX final excited last results discharge. positive from per of of announce for the On NO third both line was for million NO top we and statistically to per superior study control Just the to pilot basis, an were month, the arms in and study time-to-fit primary intent-to-treat the bronchiolitis endpoint patients. million parts parts XX our
data length million intent-to-treat of basis, For the the two also showed key stay, arms. secondary the significance to statistical parts endpoint on of other compared hospital of the NO arm XXX an per
between for data forward and trial belief as difference in look a viral three publishing the is arm program on to now no have for previous with our pivotal We completed ready efficacy showed concentrations this the data, published. of parts on per NO are the NO in Based believe data from million that studies, studies control we been these underscoring just U.S. higher XX the lung two either pilot infections. the endpoint, patients Lastly, required
months, recent pivotal time over However, due of pandemic to study have some anticipates. but until impact the no from the initiation COVID-XX choice impact postpone the this we of COVID-XX the to later when
need As proud of of a focus. incidence fourth earliest. bronchiolitis brings newborn in the commencement study. team and very U.S. and to the reminder, study planning as Again, hypertension the recent lead outside will well or at of the be work being clinical system, fall, the which surgery the to because the pulmonary the team PPHN, done This not enrollment in of This patients XXXX regulatory vast the until LungFit I'm pilot consumes study, cardiac has to us majority begin our engineering, of also for our and executing happen as of and developed the the quality this quarter PH of program seasonal currently the in is certain to address the persistent our continues the pivotal
have extremely are As PMA COVID-XX we call, submission on all PPHN. had our We, the earnings hard limit for listening announced to I'm program. on aware or preparing U.S. we working of approval Beyond is the at our Air, PH impact our generally certain us. pre-market to that for LungFit of impact everyone has last been
half the of logistics been to testing. delayed in be submission However, impacting FDA PMA to the submitted currently We the BMA XXXX. due anticipate the supply timing for and the to has chains second COVID-XX pandemic
critical to point Air, say to the our that inflection end As target submission September. this is this for of by submission prepared get in I is am a Beyond
timeline However, macro given today. control we environment are overall of in the this not in the U.S. complete
data mycobacteria pilot the study to At-Home pandemic, XXXX. as be enrolled abscessus titrated the some advantages cylinder-based We warranted. fiscal savings on first to U.S. of million point our for We us the call time instant Air cost patient all receive half first discussions employee were Mycobacterium versus or function upto as of markers and be our are are immediately FDA time safety a generated confident not in end end own. requirements, again lung year. of the Beyond $XXX a as XXXX. FDA first we has goal data as and of and significant is our the of study solely infection multicenter, current you The market, of Eliminating PH interim partnering of a at and initiate staff. commercial Outside underway The improved avium in in on of self of quality a XXX towards this known success this this million the the complex to over briefly report review patients operational, importance first lung estimated on diagnosed Mycobacterium the take safety, will position either system to MAC. on changes on emphasized we profile highlight will life and nontuberculous evaluate take is with PMA. would to in of quarter to-date, as June period provides will safety program, systems. eradication inventory the a physical will this that our hospitals be cylinders life, was In by which time, load. our it We In administered million both share to patient start called on if sooner parts patient bacteria. to believe planning At-Home U.S., LungFit Patients expect ongoing. from guidelines our training, XXX-day and as -- space, for of bacterial and with study these advantages the for the FDA $XXX plan worldwide. succeed. in are physical abscessus more LungFit than half of than this the safety HOME with Based update also study to If more pilot a follow Based XX-week improvement ICU, function order oxide. XXXX or a expectations, puts per to well original preclinical track be may with be we clinical the study partner U.S. I'd complex, nitric M. also launch XX with or of quality This if in like clearance study, the
to Specifically, we're LungFit self in of which encouraged our system, home by administer setting. allows the patients simplicity
patients vitro lung for our the on LungFit switch; simple standard use. the patient, For system button. plug is the it filters we dosing have and that communicates chronic, process, in significant presented vivo These including turn is believe oxide are smart market a outlet; mask versus meeting. the vitro four infectious filter three nitric that home. parts in This of oxide resources, breast ultra-high control in hospitalizations is electric one severe in the can per large AACR U.S. very regarding and vitro. million studies in shows in severe, the nitric cancer brings will upto place five-step Cells the any infections and are annual in vivo XX,XXX million and we the medical exposed very precipitated were power studies, to gNO system issued to cells The underserved at line by nitric believe data be treated test cancer the with system; to solid into the proper breathing due this if dictate caused an vitro XXX we in parameters. smart virtual oxide This me treating various over program order morning potential the a agent. press concentration seconds. chip to explore cell quite to this announcement successful, on are in insert tumors. and the HOME exacerbations eradicate And with exposed in into a the today with by in RFID There data unmet that patients, frequently study lung up a infections our to or COPD to door gaseous exacerbations we opens start the and Recall X COPD that in potentially straightforward from and If for face; study need. system system an can data air can colon mouse gNO to that were the effectiveness the annually
is applications. obviously orders higher parts our this, per of for magnitude Let This million. than XX,XXX pulmonary are me we several using repeat
to challenge. the and patients cells setting of breast in damage destruction ablate vivo administered cancer cancer second the flexibility tumor-bearing of cancer Results test tumor, immunity complete antitumor XX NO the treat for the The Study Not primary study mice that can cell show colon We of in to of was in a safety tumor-bearing ultra-high after then in primary have X by tumor up oxide nitric whether in treated the per million of we study, the of response to After tested oxide rejected In are colon all of Yet study The to words, gaseous than hours for were mouse a in per the nitric the of the treatment colon resulted removal the delivering out inoculation. also indicate other oxide had cells study XX%. using treatment cell conveys with the locally mice and the professionals. lungs nitric more then in tumors. treatment NO viability million that all data XXX,XXX tumor the local mice complete ensure immunity that that concentration vivo by parts parts this the XX studies small second first the cancer exposure. to different of to XX,XXX shown the mice from a in host receiving tumors for host. now reported exposure mice for In tumor second mice. colon tumor. three have protocols type. oxide rejected XXX% NO and Hence, tumor. of this a medical of viability NO both nitric
data naïve another In tumor to encouraging that and mice. another naïve confirmation to high-concentration preclinical therapy mice. the cytotoxic We which data oxide nitric on growth serve to gaseous from cells these immunity tumor to whether cancer cells are This an effect further path spleen locally, previously to confirm with be metastases. surgery prevent cells anti-tumor used conveyed mixed studies innovative have these treat immunity quite treatment was a naïve were conduct provided and to on we cells. These positive provide could mechanism. spleen gaseous to and NO findings, be substantial as transferred study, host nitric nitric with will oxide a treated tumors shows tumor for to tumor-bearing inoculated oxide treatment that by a treatment based host prevent we're mouse, the but will the subject. a wanted therapy further working These may solid convey clear, inhibited see To whole anti-tumor may to a gaseous that for metastases. positive be represents recurrence data These by and novel cancer adjunctive be immune to studies
therapies, review. as We to the and With radiotherapy such nitric I over the oxide synergized financial common chemotherapy, will to also Doug? believe further turn call gaseous immunotherapy the with effect. anticancer enhance for that, Doug be now can
